Introduction

White spot syndrome virus (WSSV) is the most serious pathogen that adversely impacts shrimp farms worldwide. An efficient vaccine would be a desirable and feasible method for controlling the spread of WSSV. There is growing evidence that various vaccines, such as inactivated WSSV vaccines [1, 2], recombinant viral subunit vaccines [3], DNA vaccines [4], and RNA vaccines [5, 6], can significantly enhance immune responses in the host and enhance resistance against WSSV-associated diseases.

More than 39 WSSV structural proteins have been identified [7, 8]. VP28, the main viral envelope protein, plays a pivotal role during viral infection, budding, entry, and virion assembly and has become the main target for exploitation of WSSV subunit vaccines [9, 10]. The expression of recombinant VP28 has been attempted in a variety of host systems, including Pichia pastoris [11], Brevibacillus brevis [12], Escherichia coli [13, 14], baculoviruses [15], silkworm pupae [16], and Bacillus subtilis [17, 18]. However, there are several disadvantages associated with these expression systems, including unsafe injection methods, high costs, long cultivation times, and difficulties in batch production. These disadvantages have resulted in the aforementioned expression systems not being considered feasible for practical applications in aquaculture. Thus, an optimal expression system for the production of a WSSV subunit vaccine is necessary and must be developed.

The eukaryotic green alga, Dunaliella salina, has been exploited as a novel bioreactor [19], as it has a very simple unicellular structure and can be cultured easily, rapidly, and cheaply. It has a high capacity for large-scale growth under natural conditions and can effectively accumulate protein products at high yields. D. salina lacks a rigid cell wall, making it a naturally occurring protoplast, which in turn makes it relatively easy to introduce exogenous genes. As a eukaryotic organism, it can facilitate transcription and translation to produce crude proteins [20]. Because it is photosynthetic, D. salina can be cultured in open photobioreactors or natural seawater. D. salina cells have a single, large, cup-shaped chloroplast which can be used as an alternative and effective expression system to nuclear expression, as “position effect”, “gene escaping” and “gene silencing” can be eliminated [21, 22]. Other valuable components, such as carotenoids, lipids, vitamins, and minerals, accumulate in D. salina, and therefore this alga has great potential for industrial and pharmaceutical applications [23]. As a bioreactor, D. salina is an optimal choice that provides the perfect opportunity for the production of a WSSV subunit vaccine.

Shrimp are the natural hosts for WSSV, and the WSSV structural gene can be introduced into D. salina cells by transformation; in turn, D. salina cells can be used as crude bait for shrimp. Furthermore, all these organisms live in the same seawater environment. Using these ecological interactions, we attempted to produce a live oral vaccine for controlling the spread of WSSV. This vaccine can be used more conveniently for shrimp than other vaccines, and it is expected to yield better immune protection.

Materials and methods

Algae strain and culture conditions

The UTEX-1644 strain of D. salina was purchased from the Culture Collection of Algae at the University of Texas (Austin, TX, USA). Under a light intensity of 50 μmol photon m−2 s−1, D. salina cells were cultured in modified PKS medium at 26 °C over 12-h night/day cycles [24]. At the logarithmic growth phase (105 cells ml−1), cells were harvested by centrifugation for subsequent transformation. During this phase, D. salina cells had uniform size, shape, and movement (Fig. 1).

Fig. 1
figure 1

Morphology of D. salina cells (400× magnification). The scale bar indicates 10 μm

Cloning and sequencing the VP28 gene

Prior to VP28 gene cloning, WSSV was purified and titrated from an infected Penaeus monodon shrimp using sucrose gradient centrifugation [3, 25]. WSSV genomic DNA was extracted using the phenol-chloroform method [10]. Using the viral DNA as template, PCR amplification was conducted using specific primers 5′-CA CCC GGG ATG GAT CTT TCT TTC ACT CTT TC-3′ and 5′-TC GAG CTC TTA CTC GGT CTC AGT GCC AGA-3′; the italics sequences represent SmaI and SacI endonuclease recognition sites, respectively), which were designed according to the coding region of VP28 (GenBank accession no. AF502435.1). Amplification reactions comprised 5 μl of PCR buffer (10×), 1 μl of template DNA, 2 μl of each primer (25 μM), 2 μl of dNTPs (25 μM), 1 μl of Taq DNA polymerase (5 U/μl) and dH2O to a volume of 50 μl. The thermal cycling conditions involved an initial denaturation step at 94 °C for 4 min, followed by 30 cycles at 94 °C for 30 s, 55 °C for 30 s and 72 °C for 1 min, and a final extension step at 72 °C for 10 min and termination at 4 °C. Amplifications were visualized by electrophoresis on 1 % (w/v) agarose gels. Amplified VP28 fragments were inserted into the pMD19-T vector (TaKaRa, Dalian, China) to yield pMD19-T-VP28 and sequenced (Sangon, Shanghai, China).

Generation of the eukaryotic expression vector

The pBI221-bar and pUΩ-GUS plasmids were obtained from the Institute of Genetics and Developmental Biology, Chinese Academy of Sciences. The pUΩ-GUS plasmid was digested using endonucleases, and the linearized pUΩ- was then collected using a DNA gel extraction kit (Axygen Biosciences, USA). Using SmaI and SacI, the VP28 fragment was excised from pMD19-T-VP28 and ligated into linearized pUΩ- to generate pUΩ-VP28. The bar box was removed from pBI221-bar by HindIII digestion and inserted into pUΩ-VP28 to produce pUΩ-VP28-bar (Fig. 2).

Fig. 2
figure 2

Schematic diagram of the pUΩ-VP28-bar vector. Bar box, bialaphos resistance gene driven by the CaMV35S promoter; Ubil, maize ubiquitin promoter; Ω, 5′ leader sequence of tobacco mosaic virus RNA; VP28, WSSV VP28 gene; Nos, nopaline synthase gene terminator. Other labels are the restriction endonuclease sites

Transformation and screening of D. salina cells

Using glass beads [24], pUΩ-VP28-bar was introduced into D. salina cells using optimized transformation parameters. Transformed D. salina cells were cultured in fresh liquid medium under dim light for 24 h and then harvested by centrifugation and plated on solid selective PKS medium containing 10 g l−1 agarose and 3 μg ml−1 phosphinothricin (PPT) to screen for positive colonies. Negative controls were prepared by treating D. salina cells using the same transformation protocol without pUΩ-VP28-bar. Independent experiments were repeated at least three times.

Reverse transcription polymerase chain reaction (RT-PCR) analysis of transformants

When the cell concentration reached 105 cells ml−1, transformed cells were collected by centrifugation and washed three times with fresh liquid medium. Following the manufacturer’s instructions, total RNA was extracted using Trizol Reagent (Invitrogen). Using the extracted total RNA as template, RT-PCR was conducted to detect VP28 gene expression. Amplification products were analyzed by electrophoresis on 10 g l−1 agarose gels. The transformed strain with the highest expression level of mRNA was selected from three transformants and used for further western blotting assays.

ELISA and western blot analysis of recombinant VP28 proteins

Proteins were extracted from the negative control and transformants using Trizol, and measured by enzyme-linked immunosorbent assay (ELISA) and western blot analysis. The concentration of proteins was determined using the Bradford assay [26]. Approximately 150 μl of total protein lysate from each transformant was used to coat ELISA plates at 37 °C overnight. After washing twice with Tris-buffered saline (TBS; 150 mM NaCl, 10 mM Tris, pH 7.4), the plate was incubated with rabbit anti-VP28 IgG in TBS for 2 h at 37 °C. Subsequently, the plate was incubated with goat anti-rabbit IgG conjugated to alkaline phosphatase (Sigma) at 37 °C for 1 h. The substrate solution was added to the plate for 20 min at 37 °C, and the absorbance at 492 nm was determined using a microplate reader.

The method of Yoganandhan et al. [27] was used for western blot detection of recombinant VP28. Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. After blocking with 3 % (w/v) skim milk, membranes were incubated with rabbit anti-VP28 IgG for 2 h, and then with goat anti-rabbit IgG conjugated with alkaline phosphatase for 1.5 h at 37 °C. NBT and BCIP were used as substrates, and protein molecular weights were estimated with Band Scan 5 software.

Vaccination experiment and WSSV challenge

The oral vaccination experiment for transgenic D. salina in animals was carried out according to the method of Fu et al. [17]. Briefly, cultures (50 ml) of transgenic D. salina cells, including Ds-VP28 and Ds-empty (1 × 108 cells ml−1; Table 1) were centrifuged, and cell pellets were resuspended in 15 ml of supernatant at 4 °C. Resuspended cells were subjected to two cycles of freeze-thawing for initial lysis of cells. Cells were then sonicated (250 W, 25 kHz, 7 s on/10 s off, 50 cycles) on ice, and lysates were observed with a microscope to ensure that D. salina cells were fully inactivated. Lysed cells were spread over 50 g of commercial crayfish feed, incubated on ice for 30 min to allow the feed to absorb lysed cellular material, and the feed was coated with fish oil. The negative and positive control pellets were coated with phosphate-buffered saline (PBS). Four groups of 20 WSSV-free crayfish were established. Each group was subjected to the vaccination experiment three times. The negative and positive control crayfish were orally administered PBS-coated feed, whereas the crayfish in groups 3 and 4 were orally administered Ds-VP28 and Ds-empty coated feed, respectively, for 10 consecutive days. Experimental crayfish were fed with coated food pellets to 5 % of their body weight. After the final vaccination, the crayfish in groups 2–4 were immediately challenged by immersing them in seawater containing WSSV stock solution (1 × 10−4 dilution) for 3 h. Negative control crayfish were challenged with PBS. All crayfish were then transferred to fresh WSSV-free seawater, and mortality at 20 days post-challenge was recorded. Dead crayfish were tested by one-step PCR to determine the presence of WSSV.

Table 1 Setup for the vaccination experiment

Statistical analysis

Data from all experiments were analyzed using a paired-samples t-test with SPSS (version16.0, Chicago, IL, USA). A P-value less than 0.05 was considered statistically significant.

Results

Gene cloning and vector construction

The PCR results revealed a specific fragment of 615 bp in lane 1 (Fig. 3A), consistent with expectations. Gene sequencing results showed that the sequence of the amplified DNA fragment was consistent with those in GenBank. Our findings demonstrate that the WSSV VP28 gene was successfully cloned and had the correct sequence, and that it could be liberated from pUΩ-VP28 (Fig. 3B). The bar box within pUΩ-VP28-bar was successfully excised (Fig. 3C).

Fig. 3
figure 3

Cloning the WSSV VP28 gene. (A) PCR amplification products of the WSSV VP28 gene. M, DNA marker; lane 1, amplification products. (B) Restriction enzyme analysis of pUΩ-VP28. Lane 1, pUΩ-VP28 digested with SmaI and SacI; 2, pUΩ-VP28; M, DNA marker. (C) Restriction enzyme analysis of pUΩ-VP28-bar. Lane 1, pUΩ-VP28-bar digested with HindIII; 2, pUΩ-VP28-bar; M, DNA marker

Transformation of D. salina

Positive D. salina transformants appeared as uniform greenish algal colonies with diameters of about 2–3 mm (Fig. 4A and B). Three colonies were selected and inoculated in selective liquid selective containing 3 μg ml−1 PPT. After incubation for 7 days, all colonies exhibited cell growth with uniform size and movement. The recombinant eukaryotic expression vector was successfully introduced into the D. salina cells.

Fig. 4
figure 4

Selective culture results for transformed D. salina cells. (A) Transformed D. salina cells containing pUΩ-VP28-bar. (B) Negative controls, D. salina cells lacking pUΩ-VP28-bar

RT-PCR analysis of transformants

RT-PCR results revealed that the predicted size of the VP28 gene, a 615-bp PCR fragment, was detected in all transformants (Fig. 5) but not in the negative controls. Sequence results indicated that the amplified DNA fragment was consistent with the coding region of the VP28 gene. PPT resistance tests demonstrated that all transformants survived repeated PPT selection and were stable for 3 months, indicating that the recombinant vector was successfully integrated into the genome of D. salina cells and stably expressed in progeny cells.

Fig. 5
figure 5

RT-PCR analysis of the VP28 gene in different transformants of D. salina. M, DNA marker; NC, negative control; lanes 1–3, various D. salina transformants

ELISA and western blot analysis of transformants

Total protein concentrations were 16.7, 16.9, and 17.1 μg μl−1 for each D. salina transformant, and 16.6 μg μl−1 for the negative control. ELISA results show that the levels of VP28 protein in transformants 1–3 were 3.04 ± 0.26, 0.99 ± 0.08, and 2.13 ± 0.17 ng mg−1, respectively (Fig. 6). No protein was detected in the negative control (Fig. 6). Approximately 78 μg of recombinant VP28 protein was obtained from 100 ml cultures of D. salina.

Fig. 6
figure 6

Analysis of VP28 expression in different transgenic D. salina strains by ELISA. NC, negative control; 1–3, various transgenic D. salina strains

Recombinant VP28 proteins appeared to be approximately 28 kDa in all three transformants and were lacking in the negative control (Fig. 7A). Our western blot results show that protein extracts from the transformant with maximal expression levels contained a band corresponding to 28 kDa (Fig. 7B). These results confirm that the recombinant VP28 protein was successfully expressed in D. salina cells and that it had specific immunologic activity.

Fig. 7
figure 7

SDS-PAGE and western blot analysis of D. salina transformants. (A) SDS-PAGE analysis of different D. salina transformants. M, protein marker; NC, negative control; T1–3, D. salina transformants. (B) Western blot analysis of the transformant with highest protein expression levels. Lane 1, recombinant VP28 protein; M, protein marker

Vaccination experiment and WSSV challenge

After vaccination, experimental crayfish were observed twice a day. Ds-VP28-vaccinated crayfish had significantly higher survival rates (59 % mortality) than the Ds-empty control and the positive control groups (100 % mortality; Fig. 8). No deaths occurred among the crayfish in the negative control group throughout the experimental period. Using PCR, dead crayfish were found to be positive for the presence of WSSV, and all randomly selected survivors were found to be negative for virus.

Fig. 8
figure 8

The temporal-mortality relationship in orally vaccinated crayfish. Cumulative mortality rates of crayfish from the experimental groups vaccinated with Ds-VP28 (●), Ds-empty (♦), positive control (▲), and negative control (■), as indicated in Table 1

Discussion

No adequate method or approach is currently available for controlling white spot disease. Initial treatments, such as reducing densities and decreasing water carrying capacities, are often infeasible because of their inefficiency and high cost [11]. Therefore, studies have focused on alternative methods of disease control, in particular vaccines against WSSV [1417]. However, given the drawbacks of most expression systems, vaccines have not been able to be suitably applied. Thus, we attempted to produce a novel subunit vaccine against WSSV using D. salina cells.

In the present study, D. salina was used as a novel expression system for producing the WSSV subunit vaccine. After transformation, PPT-resistant D. salina transformants were obtained. The WSSV VP28 gene was successfully introduced into the genome of D. salina cells and expressed, resulting in a protein with natural immunological activity. The Ds-VP28 vaccinated crayfish showed an approximate 59 % survival rate, whereas Ds-empty and positive control crayfish exhibited 100 % mortality. This result shows that protection against WSSV can be conferred in crayfish using transgenic D. salina as an oral vaccine.

The immune effects of the recombinant WSSV subunit vaccine have a direct relationship to the expression level of the target protein and its bioactivity [12]. In our previous study, the expression levels of the VP28 protein varied among different transformants. This may be attributed to the random integration of the VP28 gene into the D. salina genome at different sites. Therefore, more-detailed work involving optimization of codon dependence [28], transformation-associated genotypic modifications [29], reduction of sensitivity to proteases [30], and fusion of recombinant products with native proteins [31] should be conducted to obtain higher VP28 expression levels. Our next study will focus on the selection and effects of adjuvants, the optimal immunization procedure, the best formulation for the specific immunogen, immunization time, and dose of transgenic D. salina for shrimps.

In summary, transgenic D. salina strains successfully expressed the WSSV VP28 gene, and induced protection against WSSV in crayfish through an oral delivery approach. Our results further imply that producing an oral vaccine by D. salina is feasible for the control of WSSV infections and will also provide a new method for controlling other viral diseases in crustacean species.